Aron F Stein, PhD is currently the Vice President, Global Regulatory Affairs at Sangamo Therapeutic where he provides the vision, strategic direction and corporate regulatory approach for all gene and cell therapeutics. He has over 30 years of product development experience in pharmaceutical and biotechnology having responsibility for multiple drug approvals in both large and small companies. Aron earned his B.S. and PhD at Texas A&M University in toxicology and was a NIEHS postdoctoral fellow at University of Kansas Medical Center.
Prior to starting at Sangamo, Dr. Stein was the Vice President of Global Regulatory Affairs of Bavarian Nordic, a public Danish-based vaccine company developing viral-vector vaccines for use in infectious disease and immune-oncology. While at Bavarian, Dr. Stein established the global regulatory function in the US and EU, successfully negotiation with Health Authorities on the registration requirements for IMVAMUNE, a smallpox vaccine and for PROSTVAC, an immunotherapy for prostate cancer, and the commissioning of a new manufacturing suite. Prior to Bavarian Nordic, Dr. Stein has served in Vice President roles in Regulatory Affairs and Quality Assurance at Ionis Pharmaceuticals (formerly Isis), Abbott Laboratories, and Sequus Pharmaceuticals. Prior to that, he was the director of Regulatory Affairs at Pfizer Pharmaceuticals and a manager of Regulatory Affairs with DuPont-Merck Pharmaceuticals.
Monday, September 23
10:30 AM – 12:00 PM